Early Detection Leverage Singlera's PanSeer and ColonES methylation-based assays to position offerings for oncology clinics and research institutions seeking high-sensitivity, non-invasive cancer screening tools, with a focus on early-stage detection opportunities.

Collaborative Pathways Target potential co-development and research collaborations with pharmaceutical and biotech partners (e.g., Astellas) to integrate methylation assays into drug development pipelines and pharmacodynamics studies, expanding use cases beyond diagnostics.

Pre-Commercial Readiness Capitalize on the pre-commercial status by engaging early adopters and experimental laboratories for pilot programs, technology validation, and joint go-to-market planning to accelerate market entry once products are commercialized.

Strategic Partnerships Highlight opportunities with mid-to-large bio/pharma distributors and contract research organizations to broaden distribution networks and accelerate adoption in clinical and translational research settings.

Regulatory & Funding Position for conversations around regulatory strategy support, Breakthrough Device Designation success, and potential funding or grant partnerships to de-risk adoption and build credibility with hospital systems and research centers.